Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10757878.3Aexternal-prioritypatent/EP2473510B1/en
Application filed by Bristol-Myers Squibb CompanyfiledCriticalBristol-Myers Squibb Company
Publication of CY1115576T1publicationCriticalpatent/CY1115576T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Η παρούσα εφεύρεση παρέχει ενώσεις του τύπου Ι και φαρμακευτικώς αποδεκτά άλατα αυτών. Οι ενώσεις του τύπου Ι αναστέλλουν τη δραστικότητα κινάσης τυροσίνης του JΑΚ2, καθιστώντας έτσι αυτές χρήσιμες ως αντιπολλαπλασιαστικούς παράγοντες για τη θεραπεία καρκίνου και άλλων ασθενειών.The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of formula I inhibit the tyrosine kinase activity of JAK2, thus making them useful as antiproliferative agents for the treatment of cancer and other diseases.
CY20141100770T2009-09-032014-09-23
JAC2 Suspensions and Their Use for the Treatment of Myelodysplastic Diseases and Cancer
CY1115576T1
(en)